Kodiak Sciences (NASDAQ:KOD) Receives “Neutral” Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Kodiak Sciences (NASDAQ:KOD) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $3.00 target price on the stock.

Kodiak Sciences Trading Down 1.8 %

Shares of KOD stock opened at $2.66 on Tuesday. The stock’s 50-day moving average price is $2.65 and its 200-day moving average price is $3.30. Kodiak Sciences has a 12-month low of $1.37 and a 12-month high of $7.77. The stock has a market capitalization of $139.97 million, a price-to-earnings ratio of -0.60 and a beta of 2.35.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.01. As a group, research analysts predict that Kodiak Sciences will post -3.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Kodiak Sciences

Several large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. bought a new position in shares of Kodiak Sciences during the second quarter valued at approximately $36,000. Sanctuary Advisors LLC bought a new position in shares of Kodiak Sciences during the second quarter valued at approximately $36,000. Headlands Technologies LLC bought a new position in shares of Kodiak Sciences during the first quarter valued at approximately $50,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Kodiak Sciences during the first quarter valued at approximately $68,000. Finally, Diversified Trust Co bought a new position in shares of Kodiak Sciences during the first quarter valued at approximately $83,000. 89.06% of the stock is owned by institutional investors.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.